Skip to main content
    N

    Neuroone Medical Technologies Corp (NMTC)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $0.74
    -0.00 (-0.01%)

    Market Cap: $6.78M

    Last updated: Nov 17, 2026 at 11:00 AM ET

    Neuroone Medical Technologies Corp (NMTC) Earnings: Report Dates and Results

    Updated Aug 13, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Neuroone Medical Technologies (NMTC) is confirmed to report earnings on Dec 15, 2026, after the close. In the quarter ended Jun 30, 2026, Neuroone Medical Technologies reported EPS of -$0.28, below the -$0.22 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    52%(11/21)
    Avg Surprise
    +13.66%

    Upcoming Estimates

    Reports Dec 15, 2026 after closePeriod ending Sep 30, 2026
    EPS Consensus-$0.20
    Range-$0.20 - -$0.20
    5 analysts
    Revenue Consensus
    $3.27M
    Range$2.59M - $3.99M
    5 analysts
    Reports Feb 15, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.17
    Range-$0.22 - -$0.14
    3 analysts
    EPS Revisions
    0
    2
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.15-15.9%
    60d ago-$0.15-15.9%
    30d ago-$0.170.0%
    7d ago-$0.170.0%
    Current-$0.17
    Revenue Consensus
    $3.07M
    Range$3.05M - $3.10M
    2 analysts

    Next Report

    NMTC has a confirmed report date of Dec 15, 2026, after the close.

    NMTC Earnings Call

    The latest NMTC earnings call transcript on file is labeled 2026Q2.

    Read the 2026Q2 transcript

    Earnings History

    Of the 21 quarters below that had an estimate, NMTC beat 11, missed 6 and matched 4. Revenue for the quarter ended Jun 30, 2026 was $1.97M, up 15.9% from $1.70M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Jun 30, 2026-$0.28-$0.22-$0.26 - -$0.17-27.27%MissN/A31 up, 0 downAug 13, 2026$1.97M
    Mar 31, 2026-$0.25-$0.23-$0.30 - -$0.14-8.43%MissN/A31 up, 1 downMay 12, 2026$2.39M
    Dec 31, 2025-$0.18-$0.24-$0.24 - -$0.18+25.00%Beat-150.0%20 up, 0 downFeb 17, 2026$2.89M
    Sep 30, 2025-$0.03-$0.06N/A+46.00%BeatN/A20 up, 1 downDec 17, 2025$2.74M
    Jun 30, 2025-$0.18-$0.30N/A+40.00%BeatN/AN/A0 up, 0 downAug 14, 2025$1.70M
    Mar 31, 2025-$0.42-$0.54N/A+22.22%BeatN/AN/A0 up, 0 downMay 13, 2025$1.39M
    Dec 31, 2024$0.36-$0.60N/A+160.00%BeatN/AN/A0 up, 1 downFeb 12, 2025$3.27M
    Sep 30, 2024-$0.11-$0.09N/A-24.44%MissN/AN/AN/ADec 17, 2024$272284
    Jun 30, 2024-$0.10-$0.09N/A-12.44%MissN/AN/A1 up, 1 downAug 14, 2024$825776
    Mar 31, 2024-$0.11-$0.10N/A-10.20%MissN/AN/A1 up, 1 downMay 14, 2024$1.38M
    Dec 31, 2023-$0.84-$0.84-$0.84 - -$0.840.00%In lineN/A20 up, 0 downFeb 13, 2024$977649
    Sep 30, 2023-$0.13-$0.17-$0.18 - -$0.17+23.53%BeatN/A20 up, 0 downDec 14, 2023$741780
    Jun 30, 2023-$1.20-$1.23-$1.26 - -$1.20+2.44%BeatN/A20 up, 0 downAug 14, 2023$629906
    Mar 31, 2023-$1.26-$1.23-$1.26 - -$1.20-2.44%MissN/A20 up, 0 downMay 11, 2023$466176
    Dec 31, 2022-$0.66-$0.66-$0.66 - -$0.660.00%In lineN/A10 up, 0 downFeb 13, 2023$114579
    Sep 30, 2022-$0.09-$0.11-$0.23 - $0.01+18.18%BeatN/A20 up, 0 downDec 22, 2022$68788
    Jun 30, 2022-$1.02-$1.35-$1.44 - -$1.26+24.44%BeatN/A20 up, 0 downAug 11, 2022$32049
    Mar 31, 2022-$1.14-$1.20-$1.26 - -$1.14+5.00%BeatN/A20 up, 0 downMay 12, 2022$36584
    Dec 31, 2021-$1.08-$1.14-$1.14 - -$1.08+5.26%BeatN/A20 up, 0 downFeb 14, 2022$33748
    Sep 30, 2021-$0.22-$0.22-$0.25 - -$0.220.00%In lineN/A20 up, 0 downDec 15, 2021$48336
    Jun 30, 2021-$0.25-$0.25N/A0.00%In lineN/AN/AN/AAug 13, 2021$40096
    Mar 31, 2021-$0.64N/AN/AN/AN/AN/AN/AN/AMay 14, 2021$18240
    Dec 31, 2020-$0.09N/AN/AN/AN/AN/AN/AN/AFeb 16, 2021$71474
    Sep 30, 2020-$0.03N/AN/AN/AN/AN/AN/AN/ADec 8, 2020$1.93M
    Jun 30, 2020-$0.44N/AN/AN/AN/AN/AN/AN/AAug 13, 2020N/A
    Mar 31, 2020-$0.10N/AN/AN/AN/AN/AN/AN/AMay 14, 2020N/A
    Dec 31, 2019-$0.34N/AN/AN/AN/AN/AN/AN/AJan 28, 2020N/A
    Sep 30, 2019-$0.10N/AN/AN/AN/AN/AN/AN/ADec 20, 2019N/A
    Jun 30, 2019-$0.14N/AN/AN/AN/AN/AN/AN/AAug 14, 2019N/A
    Mar 31, 2019-$0.20N/AN/AN/AN/AN/AN/AN/AMay 10, 2019N/A
    Dec 31, 2018-$0.14N/AN/AN/AN/AN/AN/AN/AFeb 14, 2019N/A
    Sep 30, 2018-$0.25N/AN/AN/AN/AN/AN/AN/ADec 12, 2018N/A
    Jun 30, 2018-$0.16N/AN/AN/AN/AN/AN/AN/AAug 13, 2018N/A
    Mar 31, 2018-$0.17N/AN/AN/AN/AN/AN/AN/AApr 16, 2018N/A
    Dec 31, 2017-$0.52N/AN/AN/AN/AN/AN/AN/AMar 31, 2018N/A
    Sep 30, 2017-$0.63N/AN/AN/AN/AN/AN/AN/ANov 14, 2017N/A
    Jun 30, 2017-$0.56N/AN/AN/AN/AN/AN/AN/AAug 14, 2017N/A
    Mar 31, 2017-$0.66N/AN/AN/AN/AN/AN/AN/AApr 17, 2017N/A
    Dec 31, 2016-$0.42N/AN/AN/AN/AN/AN/AN/AMar 31, 2017N/A
    Sep 30, 2016-$0.14N/AN/AN/AN/AN/AN/AN/ANov 21, 2016N/A
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Sep 30, 2026 was -$0.71, after -$0.27 the year before. It was -$2.27 for the year ended Sep 30, 2017, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Sep 30, 2026-$0.71N/A
    Sep 30, 2025-$0.27N/A
    Sep 30, 2024-$1.16N/A
    Sep 30, 2023-$3.25N/A
    Sep 30, 2022-$3.33N/A
    Sep 30, 2021-$1.20N/A
    Sep 30, 2020-$0.91N/A
    Sep 30, 2019-$0.58N/A
    Sep 30, 2018-$1.10N/A
    Sep 30, 2017-$2.27N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 3,500 words across 6 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q2Jun 30, 20263,5396
    2026Q1Mar 31, 20262,7625
    2025Q4Dec 31, 20254,4845
    2025Q3Sep 30, 20252,4904
    2025Q2Jun 30, 20252,6855
    2025Q1Mar 31, 20252,6024
    2024Q4Dec 31, 20241,9263
    2024Q3Sep 30, 20241,4633

    2026Q2 Earnings Call

    Opening remarks

    David Rosa Chief Executive Officer Thank you, operator, and thank you to everyone for joining us today. I'd like to welcome you to our second quarter fiscal 2026 financial results conference call. Product revenue for the OneRF brain ablation system in the second quarter of fiscal 2026 grew 72% year-over-year to $2.4 million compared to $1.4 million in the second quarter of fiscal 2025. We continue to be energized by reports of the positive impact this therapy is having on people's lives. Most recently, the U.S. Department of Veterans Affairs published an article regarding Dr. Garrett Banks' experience with the technology. The article discussed the challenges that Navy veteran Derek Harpole had to endure after being diagnosed with epilepsy. For more than two decades, he was unable to work, drive or hunt alone. Dr. Banks and his team at the Houston VA performed their first OneRF brain ablation procedure on Derek. He woke up the morning after the procedure "bright-eyed and bushy-tailed," in his words. With his seizures dramatically reduced, he now has hope that he can regain the life he once had. Through our partnership with Zimmer Biomet, our goal is to expand this therapy into new centers in order to change other people's lives as well. The company also had several important corporate developments I'd like to highlight. First, we appointed David Wambeke as Chief Business Officer to lead our drug delivery program, oversee Investor Relations and support business development. As a meaningful sign of his confidence, David purchased 1 million shares of NeuroOne common stock on a pre-split basis. We were also pleased to announce that we regained compliance with NASDAQ's minimum bid price requirement following a 1-for-6 reverse split of our common stock. Finally, we are always excited to welcome new investors, and we're pleased to learn a new high net worth investor acquired approximately 7.4% of our outstanding common stock in the open market. Now let's move on to discuss the exciting progress we have made with our existing product portfolio. Regarding our OneRF brain ablation system, as I mentioned in the opening, we experienced 72% year-over-year revenue growth. We believe there is upside for growth domestically and internationally. Domestically, we are developing a webinar that will highlight clinical experience with the device that we can expand exposure to neurologists and neurosurgeons that may not be aware of the exciting results that are being reported. With respect to international commercialization progress, we completed the Stage 2 audit of our Minnesota facility for ISO 13485 certification and remain bullish on certification in the latter part of 2026, which is a key step in the process of enabling international distribution of our products.

    Frequently Asked Questions About NMTC

    When is Neuroone Medical Technologies's next earnings date?

    Neuroone Medical Technologies's next earnings report is confirmed for Dec 15, 2026, after the close.

    Did NMTC beat earnings estimates last quarter?

    No. Neuroone Medical Technologies reported EPS of -$0.28 for the quarter ended Jun 30, 2026, below the -$0.22 estimate by 27.27%.

    What EPS do analysts expect from NMTC next quarter?

    The consensus EPS estimate for Neuroone Medical Technologies for the quarter ended Sep 30, 2026 is -$0.20 from 5 analysts, with estimates from -$0.20 to -$0.20.

    How often does NMTC beat earnings estimates?

    Neuroone Medical Technologies beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +29.13%.

    Does NMTC report before or after the market opens?

    Neuroone Medical Technologies is confirmed to report on Dec 15, 2026, after the market closes.